Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (4881)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Apr 15, 2023 (publication date) through Jun 4, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699 [PMID: 37123056 DOI: 10.4251/wjgo.v15.i4.689] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm |
| Number | Citing Articles |
| 1 |
Ya Gao, Chunxia Du, Yan Xu, Xinqi Cheng, Haitao Zhao, Fang Jiang, Ninghai Cheng, Yang Xiang, Yuelun Zhang, Yuanmeng Li, He Liu, Xiaofeng Chai, Xiaolan Lian, Weigang Zhao, Naishi Li. Optimal Levothyroxine Dosing Strategy for Immune Checkpoint Inhibitor-related Hypothyroidism: A Retrospective Study. The Journal of Clinical Endocrinology & Metabolism 2025; doi: 10.1210/clinem/dgaf260
|
| 2 |
Taito Fukushima, Satoshi Kobayashi, Makoto Ueno. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors. Japanese Journal of Clinical Oncology 2024; 54(9): 949 doi: 10.1093/jjco/hyae067
|
| 3 |
Zhengzheng Ji, Ding Fang, Jiasong Li, Ruijie Cao, Handong Wang, Zesong Meng, Zhanjun Guo, Yue Zhao. Serum Alpha-fetoprotein Associated with Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma: A Meta-Analysis and a Retrospective Cohort Study. Hepatitis Monthly 2025; 24(1) doi: 10.5812/hepatmon-145022
|
| 4 |
Miki Kawano, Yoshihiko Yano, Atsushi Yamamoto, Eiichiro Yasutomi, Yuta Inoue, Jun Kitadai, Ryutaro Yoshida, Takanori Matsuura, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama. Risk Factors for Immune Checkpoint Inhibitor-Induced Liver Injury and the Significance of Liver Biopsy. Diagnostics 2024; 14(8): 815 doi: 10.3390/diagnostics14080815
|
| 5 |
Ling Fan, Jintong Na, Tieliu Shi, Yuan Liao. Hepatoblastoma: From Molecular Mechanisms to Therapeutic Strategies. Current Oncology 2025; 32(3): 149 doi: 10.3390/curroncol32030149
|
| 6 |
Xiu Chen, Liqiu Kou, Xiaolu Xie, Song Su, Jun Li, Yaling Li. Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma. Immunology 2024; 172(1): 21 doi: 10.1111/imm.13751
|